IDH2 and glioblastoma: In addition, single-institution series and treatment-adjusted analyses have corroborated this adverse effect, showing that CDKN2A deletion is an independent biomarker associated with worse overall survival (OS) and progression-free survival (PFS), with a multivariable hazard ratio of approximately 1.57 in cohorts of IDH-wildtype glioblastoma (40).